HPV Vaccine Study Admits Unanswered Questions, Questions Clinical Value

HPV Vaccine Study Admits Unanswered Questions, Questions Clinical Value

An article published in the Journal of Clinical Investigation, authored by defenders of the human bicho vaccine, explicitly acknowledges that there are 'several important unanswered questions that make it difficult to predict the actual impact of the vaccine.' The text, translated and circulated in an economic discussion forum, has peine the debate on what is being sold when discussing vaccine efficacy: demonstrated clinical protection or merely a reduction in a laboratory marker?

The paper, which is not critical of the vaccine but rather supportive, estimates that in the best-case scenario—assuming 90% specific efficacy per strain—the reduction in CIN2+ lesions in industrialized countries would be between one-third and one-half. In other words, the vaccine would not eliminate screening: vaccinated women should continue to undergo routine detection tests. The text itself insists on educating healthcare professionals and patients about this limitation.

What the Cited Trial Actually Measures

The study presented as primary evidence—published in PubMed—trinc women for a median of 17.4 months. The result: zero persistent HPV-16 infections in the vaccinated group compared to 3.8 per 100 woman-years in the placebo group. A p-value of less than 0.001 is displayed as proof of statistical success.

The objection raised is twofold. First, the endpoint is not a clinical disease but the detection of viral DNA via PCR in two or more visits. Second, and more importantly: some question where the evidence is that the presence or absence of this DNA predicts actual present or future disease. This is not a rhetorical question. In the field of HIV, some argue that viral load was used for years as a surrogate marker without a clear correlation with disease pogre, something Kary Mullis, Nobel Prize in Chemistry for the invention of PCR, publicly questioned.

Surrogate markers, they call them. Markers that move, but which some doubt that moving in the right direction means anything for the patient.

The Calculation That Disproves the Efficacy Headline

If the result is translated into absolute numbers, the reduction is 3.8 percentage points: from 3.8% persistent infection in the placebo group to 0% in the vaccinated group. Some argue that the absolute improvement is lower than the margin of error of the PCR itself. The percentage of 'improvement' would therefore be measurement noise.

The p-value measures whether the result is attributable to chance, not whether it is clinically relevant. A statistically significant result can be clinically irrelevant if the effect is minuscule. This distinction, which any biostatistics manual covers, is blurred when the headline says '100% efficacy.'

---

Adverse Effects Not Detailed in the Package Insert

The debate then shifts to the components. Ingredients such as bovine serum, sorbitol, or gelatin are listed, associated by these voices with connective tissue disorders, gastrointestinal problems, or allergic reactions. No primary study demonstrating causality between these excipients and these conditions is provided in the material.

The case of a minor with fevers up to 40 degrees for five days after vaccination, accompanied by joint pain, is also recounted, with the doctor attributing it to a 'seasonal bicho.' This is an individual testimony, not proof of causality, but it illustrates the distrust fueling skepticism.

The Unfading Suspicion: Vaccines Without Placebo Trials?

One of the most incisive lines of debate is the absence of randomized placebo-controlled trials for many vaccines, as claimed. It is asserted that there are thousands of such studies for paracetamol or aspirin, but very few for vaccines. When requesting a flu trial, the most recent one found is from 1991. And in the 1993 adverse effects trial, involving 900 vaccinated and 900 placebo participants, 210 adverse reactions were recorded in the vaccinated group compared to 127 in the placebo group. The summary labels them as 'mild,' but they include flu-like syndromes.

The hovering question is uncomfortable: if the placebo also produces adverse effects, what exactly is being measured?

From HPV Vaccine to Collapse of Trust

The thread leads to a broader issue: trust in health institutions. Several messages anticipate that, after what was experienced in 2020, many parents will no longer vaccinate their children without reading all the evidence first. 'From 2020 NOT ONE MORE to children,' summarizes one intervention. Others defend that vaccines have reduced child mortality and that countries with better coverage live longer and better.

The JCI paper, by admitting there are unanswered questions, provides ammunition for both sides. To critics, because it confirms that clinical efficacy is not demonstrated. To defenders, because the same text concludes that, under certain assumptions, the impact would be notable. The difference is that the assumptions are not data.

---

Ultimately, the staggering fact is not the p-value or the efficacy percentage. It is that the very article used to defend the vaccine begins by admitting that its real impact is unknown.